Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single…

Background: Anticancer drugs can cause cardiotoxicity. Chemotherapy with antracyclines is associated with electrocardiographic alterations. Among the targeted therapies QTc aberrations were reported upon treatment with the anti HER2/neu antibody trastuzumab. Methods: In this observational study we assessed the cardiac safety in 19 adjuvant treated breast cancer patients. All 9 HER2/neu positive breast cancer patients were assigned to receive 4 cycles of E90C600 i.v. q3w followed by 4 cycles of doxetaxel100 q3w combined with trastuzumab q3w up to 18 cycles. As a control group we included 10 HER2/neu positive brea…